Merck Sharp & Dohme LLC
This is a phase 2 study of the pharmacokinetics, safety, and efficacy of oral doravirine/islatravir (100 mg/0.25 mg) \[MK-8591A\] in pediatric participants with human immunodeficiency virus type 1 (HIV-1) infection who are virologically suppressed or treatment-naive. The Base Study will last from Day 1 to Week 96. At Week 96, participants will be given the option to participate in an optional Study Extension and receive DOR/ISL until Week 240 or until it becomes commercially accessible, whichever is first.
Inclusion Criteria: * Pediatric participant with HIV-1 \<18 years of age * Body weight ≥35 kg * Is TN (HIV-1 positive with plasma HIV-1 RNA ≥500 copies/mL) or VS (HIV-1 positive at screening with plasma HIV-1 RNA \<50 copies/mL AND has received stable, continuous 2- or 3-drug antiretroviral therapy (ART) for ≥3 months prior to providing informed consent) Exclusion Criteria: * HIV-2 infection * Hypsensitivity/contraindication to any components of study medication or as determined by the investigator * Has an active diagnosis of hepatitis due to any cause * history of malignancy ≤5 years prio…
DOR/ISL 100 mg/0.25 mg tablet taken by mouth qd
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.